Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ESG
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
May 31, 2019 7:30am EDT

Rigel to Present at Jefferies 2019 Healthcare Conference

May 16, 2019 7:30am EDT

Rigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia

May 07, 2019 4:01pm EDT

Rigel Announces First Quarter 2019 Financial Results and Provides Company Update

Apr 30, 2019 7:30am EDT

Rigel Announces Conference Call and Webcast to Report First Quarter 2019 Financial Results and Company Update

Mar 26, 2019 7:30am EDT

Rigel Welcomes Jane Wasman to Board of Directors

Feb 28, 2019 4:01pm EST

Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

Feb 21, 2019 7:30am EST

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results

Jan 23, 2019 7:30am EST

Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

Jan 07, 2019 7:30am EST

Rigel Pharmaceuticals Provides Business Update

Jan 03, 2019 4:30pm EST

Rigel to Present at the 37th Annual J.P. Morgan Healthcare Conference

  • Previous
  • 1…
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • …42
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin